<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656070</url>
  </required_header>
  <id_info>
    <org_study_id>HLS02/2011-1.0-09-11-2010</org_study_id>
    <secondary_id>2011-000593-54</secondary_id>
    <nct_id>NCT01656070</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in HIV-infected Youth</brief_title>
  <official_title>Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Along with its effects on bone metabolism, vitamin D is an important modulator of the immune
      system. Experimental studies have shown that the active metabolite of vitamin D [1,25(OH)2D]
      is able to skew the T cell compartment into a more anti-inflammatory state, with inhibition
      of Th1 and Th17 cells and promotion of Th2 and T regulatory subsets.

      In the context of HIV infection, in which Th1 subpopulations are devoted to inhibit viral
      replication, any alteration of the Th1/Th2 balance would be of concern.

      The aim of this Randomized Controlled Trial is to test wether oral supplementation with
      cholecalciferol could be able: 1) to improve vitamin D status and, 2) to play an
      immunomodulatory role, in vertically HIV-infected children and young adults with
      hypovitaminosis D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is increasing evidence that hypovitaminosis D is common in the general population.

      Low dietary intake of vitamin D and reduced exposure to sunlight are probably the major risk
      factors. A high prevalence of hypovitaminosis D has been described in HIV-infected adults,
      and children. HIV infection itself and antiretroviral (ARV) treatment may be responsible for
      alteration of vitamin D metabolism. For instance, studies have shown a significant decrease
      in serum 25-hydroxyvitamin-D [25(OH)D] concentration in adults receiving non-nucleoside
      reverse transcriptase inhibitors (NNRTIs). Whatever the cause(s) of hypovitaminosis D,
      because of the importance of vitamin D in bone health, randomized controlled trials (RCT)
      have been performed to test whether vitamin D supplementation can improve vitamin D status
      and bone mineral metabolism in HIV-infected children and adolescents.

      Along with its effects on bone metabolism, vitamin D is an important modulator of the immune
      system. The vitamin D receptor (VDR) is found in high concentrations in activated T
      lymphocytes, in small amounts in monocyte/macrophage cells while B lymphocytes do not contain
      detectable amounts of VDR.

      Experimental studies have shown that the active di-hydroxylated metabolite of vitamin D
      [1,25(OH)2D] is able to skew the T cell compartment into a more anti-inflammatory state, with
      inhibition of Th1 and Th17 cells and promotion of Th2 and T regulatory (Treg) subsets.

      In the context of HIV infection, in which Th1 subpopulations are devoted to inhibit viral
      replication, 16 any alteration of the Th1/Th2 balance would be of concern.

      Although all the biological effects of vitamin D are mediated by the 1,25(OH)2D, it is the
      25(OH)D to be routinely quantified because of its longer half-life.17 However, HIV-infected
      subjects may have a defective 1α-hydroxylation of 25(OH)D. Thus, it is important to evaluate
      the effects of vitamin D supplementation both in terms of 25(OH)D and 1,25(OH)2D responses.

      This repeated-measures parallel-group RCT is aimed to test wether a 12-month oral
      supplementation with cholecalciferol (vitamin D3) is able: 1) to increase serum 25(OH)D and
      1,25(OH)2D levels and, 2) to affect T-cell phenotype in vertically HIV-infected children and
      young adults with hypovitaminosis D and stable HIV-disease.

      Main outcome: to determine the frequency of hypovitaminosis D at 12-month of follow-up among
      subjects supplemented with oral cholecalciferol versus subjects receiving placebo.

      Secondary outcome: to investigate correlations - if any - between serum vitamin D
      concentration and markers of immune activation (i.e. Th1-, Th2-, Th17- and Treg-lymphocytes
      count, T-lymphocyte VDR expression)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of Hypovitaminosis D [serum 25(OH)D &lt; 30 ng/mL] in the Vitamin D receiving group vs placebo group</measure>
    <time_frame>12 months</time_frame>
    <description>Vertically HIV-infected patients aged &lt;30 years and with serum 25(OH)D &lt; 30 ng/mL were randomized into the vitamin D or placebo group. At baseline (0 months), 3, 6 and 9 months, the intervention group received orally 100000 IU of cholecalciferol. Serum 25(OH)D, 1,25(OH)2D, PTH and CD4+ T cells were assessed 3 months before baseline, at 0, 3, 6, 9 and 12 months, while Th1-, Th2-, Th17- and Treg-subsets and T-lymphocyte vitamin D receptor at 0, 3 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of oral cholecalciferol supplementation on T cell phenotype in vertically HIV-infected youth with stable HIV diseases</measure>
    <time_frame>12 months</time_frame>
    <description>Vertically HIV-infected patients aged &lt;30 years and with serum 25(OH)D &lt; 30 ng/mL were randomized into the vitamin D or placebo group. At baseline (0 months), 3, 6 and 9 months, the intervention group received orally 100000 IU of cholecalciferol. CD4+ T-cells were assessed 3 months before enrollment (-3 months), at baseline (0 months) and at each visit thereafter (3, 6, 9 and 12 months). T-lymphocyte VDR expression and Th1-, Th2-, Th17- and Treg-lymphocytes were measured at 0, 3 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV Disease</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hypovitaminosis D</condition>
  <condition>Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral cholecalciferol 1000000 UI (vitamin D3).
At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo
At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral cholecalciferol 1000000 UI (vitamin D3)</intervention_name>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>DIBASE - ABIOGEN PHARMA Spa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vertically acquired HIV infection

          -  age &lt; 30 years

          -  serum 25(OH)D concentration &lt; 30 ng/mL

          -  signed written informed consent

        Exclusion Criteria:

          -  hyperparathyroidism, as detected by an intact serum parathyroid hormone (PTH) ≥ 65
             pg/mL

          -  Black ethnic group

          -  any supplementation with vitamin D in the previous 12 months

          -  use of any treatment known to alter vitamin D status in the previous 6 months
             (excluding ARV)

          -  any concomitant severe illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Vincenzo Zuccotti, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatrics, L. Sacco Hospital, University of Milan, Milan, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Paediatrics - L. Sacco Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-97-101.</citation>
    <PMID>16315387</PMID>
  </reference>
  <reference>
    <citation>Bischoff-Ferrari HA. &quot;Vitamin D - why does it matter?&quot; - defining vitamin D deficiency and its prevalence. Scand J Clin Lab Invest Suppl. 2012;243:3-6. doi: 10.3109/00365513.2012.681938.</citation>
    <PMID>22536756</PMID>
  </reference>
  <reference>
    <citation>Kuehn EW, Anders HJ, Bogner JR, Obermaier J, Goebel FD, Schlöndorff D. Hypocalcaemia in HIV infection and AIDS. J Intern Med. 1999 Jan;245(1):69-73.</citation>
    <PMID>10095819</PMID>
  </reference>
  <reference>
    <citation>Rodríguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses. 2009 Jan;25(1):9-14. doi: 10.1089/aid.2008.0183.</citation>
    <PMID>19108690</PMID>
  </reference>
  <reference>
    <citation>Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006 May;83(5):1135-41.</citation>
    <PMID>16685057</PMID>
  </reference>
  <reference>
    <citation>Rutstein R, Downes A, Zemel B, Schall J, Stallings V. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011 Oct;30(5):624-8. doi: 10.1016/j.clnu.2011.02.005. Epub 2011 Jun 8.</citation>
    <PMID>21641097</PMID>
  </reference>
  <reference>
    <citation>Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, Burger DM, Bravenboer B, Koopmans PP, Van Der Ven AJ. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375-82. doi: 10.1089/aid.2008.0058.</citation>
    <PMID>18928396</PMID>
  </reference>
  <reference>
    <citation>Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, Magenta L, Calmy A, Vergopoulos A, Bischoff-Ferrari HA; Swiss HIV Cohort Study. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010 May 15;24(8):1127-34. doi: 10.1097/QAD.0b013e328337b161.</citation>
    <PMID>20168200</PMID>
  </reference>
  <reference>
    <citation>Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, Guillot P, Duvivier C, Billaud E, Raffi F. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother. 2012 Sep;67(9):2222-30. doi: 10.1093/jac/dks176. Epub 2012 May 15.</citation>
    <PMID>22589455</PMID>
  </reference>
  <reference>
    <citation>Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010 Nov 23;7:40. doi: 10.1186/1742-6405-7-40.</citation>
    <PMID>21092280</PMID>
  </reference>
  <reference>
    <citation>Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009 Jan;123(1):e121-6. doi: 10.1542/peds.2008-0176. Erratum in: Pediatrics. 2009 May;123(5):1437.</citation>
    <PMID>19117833</PMID>
  </reference>
  <reference>
    <citation>Arpadi SM, McMahon DJ, Abrams EJ, Bamji M, Purswani M, Engelson ES, Horlick M, Shane E. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012 Mar;95(3):678-85. doi: 10.3945/ajcn.111.024786. Epub 2012 Jan 18.</citation>
    <PMID>22258265</PMID>
  </reference>
  <reference>
    <citation>Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000 Feb 15;374(2):334-8.</citation>
    <PMID>10666315</PMID>
  </reference>
  <reference>
    <citation>Sloka S, Silva C, Wang J, Yong VW. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011 May 24;8:56. doi: 10.1186/1742-2094-8-56.</citation>
    <PMID>21605467</PMID>
  </reference>
  <reference>
    <citation>Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010 Aug;10(4):482-96. doi: 10.1016/j.coph.2010.04.001. Epub 2010 Apr 27. Review.</citation>
    <PMID>20427238</PMID>
  </reference>
  <reference>
    <citation>Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, Hoelzer D, Rossol R. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 1997 Jul 15;11(9):1111-8.</citation>
    <PMID>9233457</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Haug CJ, Aukrust P, Haug E, Mørkrid L, Müller F, Frøland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998 Nov;83(11):3832-8.</citation>
    <PMID>9814454</PMID>
  </reference>
  <reference>
    <citation>Ryan P. Random allocation of treatments in blocks. Stata Journal;8:594, 2008</citation>
  </reference>
  <reference>
    <citation>Rabe-Hesketh S and Skrondal A, Multilevel and Longitudinal Modeling Using Stata, Volume I: Continuous Responses. Stat Methods Med Res. 2016 Dec;25(6):3069.</citation>
    <PMID>27852809</PMID>
  </reference>
  <reference>
    <citation>Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Miller TL. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):339-46.</citation>
    <PMID>16131991</PMID>
  </reference>
  <reference>
    <citation>Signorello LB, Shi J, Cai Q, Zheng W, Williams SM, Long J, Cohen SS, Li G, Hollis BW, Smith JR, Blot WJ. Common variation in vitamin D pathway genes predicts circulating 25-hydroxyvitamin D Levels among African Americans. PLoS One. 2011;6(12):e28623. doi: 10.1371/journal.pone.0028623. Epub 2011 Dec 21.</citation>
    <PMID>22205958</PMID>
  </reference>
  <reference>
    <citation>Haug C, Müller F, Aukrust P, Frøland SS. Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis. 1994 Apr;169(4):889-93.</citation>
    <PMID>7907645</PMID>
  </reference>
  <reference>
    <citation>Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, Bretzel RG. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003 May;46(4):221-7.</citation>
    <PMID>12799147</PMID>
  </reference>
  <reference>
    <citation>Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, Bitnun A. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011 Dec;159(6):951-7. doi: 10.1016/j.jpeds.2011.06.010. Epub 2011 Aug 4.</citation>
    <PMID>21820130</PMID>
  </reference>
  <reference>
    <citation>Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001 Nov 1;167(9):4974-80.</citation>
    <PMID>11673504</PMID>
  </reference>
  <reference>
    <citation>Fazekas de St Groth B, Landay AL. Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS. 2008 Mar 30;22(6):671-83. doi: 10.1097/QAD.0b013e3282f466da. Review.</citation>
    <PMID>18356596</PMID>
  </reference>
  <reference>
    <citation>Aandahl EM, Michaëlsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004 Mar;78(5):2454-9.</citation>
    <PMID>14963140</PMID>
  </reference>
  <reference>
    <citation>Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002 Sep 15;169(6):3400-6.</citation>
    <PMID>12218162</PMID>
  </reference>
  <reference>
    <citation>Bang U, Kolte L, Hitz M, Dam Nielsen S, Schierbeck LL, Andersen O, Haugaard SB, Mathiesen L, Benfield T, Jensen JE. Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials. 2012 May-Jun;13(3):162-70. doi: 10.1310/hct1303-162.</citation>
    <PMID>22592096</PMID>
  </reference>
  <reference>
    <citation>D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998 Jan 1;101(1):252-62.</citation>
    <PMID>9421488</PMID>
  </reference>
  <reference>
    <citation>Shearer GM, Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res Hum Retroviruses. 1998 Jun;14 Suppl 2:S149-52. Review.</citation>
    <PMID>9672232</PMID>
  </reference>
  <reference>
    <citation>Clerici M, Seminari E, Maggiolo F, Pan A, Migliorino M, Trabattoni D, Castelli F, Suter F, Fusi ML, Minoli L, Carosi G, Maserati R; Master Group. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS. 2002 Sep 6;16(13):1767-73.</citation>
    <PMID>12218388</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Gian Vincenzo Zuccotti</investigator_full_name>
    <investigator_title>Gian Vincenzo Zuccotti, Associate Professor of Pediatrics, Chief of Department of Pediatrics at L. Sacco Hospital</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>immunity</keyword>
  <keyword>T cell phenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

